550 related articles for article (PubMed ID: 26487055)
1. Immune checkpoint inhibitors: a new frontier in bladder cancer.
Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
4. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for bladder cancer: rediscovering an old friend.
Voskoboynik M; Rudman S; Arkenau HT; Hughes S; Chowdhury S
BJU Int; 2016 May; 117(5):721-4. PubMed ID: 26389688
[No Abstract] [Full Text] [Related]
7. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Thibault C
Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Zibelman M; Ramamurthy C; Plimack ER
Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
[TBL] [Abstract][Full Text] [Related]
12. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
13. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
Dhariwal R; Pindoria N; Dasgupta P; Khan MS
BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
[No Abstract] [Full Text] [Related]
14. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
15. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
16. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
17. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
Siefker-Radtke A; Curti B
Nat Rev Urol; 2018 Feb; 15(2):112-124. PubMed ID: 29205200
[TBL] [Abstract][Full Text] [Related]
19. The immune checkpoint inhibitors: where are we now?
Webster RM
Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
[No Abstract] [Full Text] [Related]
20. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
